There were 1,579 press releases posted in the last 24 hours and 429,059 in the last 365 days.

Evolus Appoints Crystal Muilenburg as Vice President Corporate Communications & Public Relations

NEWPORT BEACH, Calif., Feb. 27, 2019 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company focused on delivering breakthrough products, today announced the appointment of Crystal Muilenburg as Vice President, Corporate Communications & Public Relations. 

“Crystal brings a depth of experience in corporate communications, public relations and marketing at industry leading companies. She shaped public perception and built awareness for many of the aesthetic industry’s most popular brands,” said David Moatazedi, President and Chief Executive Officer of Evolus.  “Crystal joins our team at a critical point in the history of the company and will be a significant asset as we drive towards a Spring launch of Jeuveau™.”

Crystal has nearly two decades of experience in corporate communications, public relations, advocacy, society relations, strategic marketing and commercial marketing for mid-cap and start-up enterprises. Most recently, Crystal was head of global strategic marketing at Sienna Biopharmaceuticals, a clinical-stage medical dermatology company, where she also supported the company’s corporate branding and corporate communications activities.  Prior to Sienna, Crystal spent more than a decade at Allergan serving in various leadership positions in corporate communications and public relations and U.S. and international marketing, specifically in medical aesthetics, where she built a deep expertise in brand awareness and consumer activation strategies while marketing directly to women and influencers.  Crystal earned a B.S. degree in Biology from California Polytechnic State University, San Luis Obispo. 

About Evolus, Inc.

Evolus is a performance beauty company with a customer-centric approach focused on delivering breakthrough products. In 2019, the U.S Food and Drug Administration approved Jeuveau™ (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure™ technology. Jeuveau™ is powered by Evolus' unique technology platform and is designed to transform the aesthetic market by eliminating the friction points existing for customers today. Visit us at:

Jeuveau™ is a trademark of Evolus, Inc.

Hi-Pure™ is a trademark of Daewoong Pharmaceutical Co, Ltd.

Evolus Contacts:

Investor Contacts:
Ashwin Agarwal, Evolus, Inc.
Vice President Finance, Investor Relations & Treasury
Tel: +1-949-284-4559

Brian Johnston, The Ruth Group
Tel: +1-646-536-7028

Media Contact:
Crystal Muilenburg, Evolus, Inc.
Vice President, Corporate Communications & Public Relations
Tel: +1-949-284-4506

Evolus Logo Nov 2018.png